2026 Global: Animal Model Market-Competitive Review (2032) report
Description
The 2026 Global: Animal Model Market-Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for animal model market by geography and historical trend. The scope of the report extends to sizing of the animal model market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Charles River Laboratories, The Jackson Laboratory (JAX), Taconic Biosciences, genOway, Janvier Labs, Biocytogen, Cyagen, Crown Bioscience, Inotiv, and Envigo (now part of larger service groups) are widely recognized as ten major companies shaping the global animal model market. Charles River is a market leader with an integrated portfolio spanning standard and specialized strains, genetically engineered models, phenotyping and regulatory support, and a global production and distribution network that serves pharmaceutical, biotech, CRO and academic clients. The Jackson Laboratory is notable for its long history in transgenic and targeted mutant mouse development, deep genetics expertise, extensive strain repositories and phenotyping resources used across translational research and preclinical discovery. Taconic distinguishes itself through custom genetically engineered rodent models, immuno‑oncology and microbiome models, and integrated breeding and colony management platforms that support rapid turnaround for complex study requirements. genOway and Janvier Labs together represent European strengths: genOway for proprietary platforms delivering reproducible gene‑edited rodent and cell models tailored to regulatory needs, and Janvier for high‑quality breeding, traceability and biosecurity that underpin neuroscience, pharmacology and infectious‑disease research in the region.
Biocytogen and Cyagen are major China‑based providers that have scaled rapid, cost‑competitive CRISPR and gene‑targeting pipelines to meet rising regional and global demand for humanized, immuno‑oncology and multi‑allelic models; both emphasize fast model generation, validation and commercial production capacity for biotech and pharma customers. Crown Bioscience and Inotiv (including acquired units) operate as vertically integrated service providers and CRO partners that combine model provision with in vivo study execution, phenotyping and toxicology services—Crown with strong translational oncology and Asia‑Pacific presence, and Inotiv with broad toxicology, surgical and specialized model capabilities across North America and Europe. Envigo, historically a major supplier of research models with a focus on welfare and flexible logistics, has been folded into larger service portfolios and remains cited among core capacity holders in industry analyses. These companies collectively respond to market drivers such as growth in oncology and immunology research, wider adoption of CRISPR/Cas gene editing, and demand for humanized and disease‑specific models while contending with regulatory and ethical pressures that encourage refinement and alternatives.
Market positioning among these ten firms reflects differences in specialization, scale and service integration: Charles River and JAX emphasize breadth, IP and translational resources; Taconic, Cyagen and genOway prioritize custom engineered models and fast CRISPR pipelines; Biocytogen and Crown leverage regional scale and oncology focus; Janvier and Envigo highlight breeding quality, biosecurity and traceability; and Inotiv emphasizes end‑to‑end CRO capabilities and toxicology services. Strategic moves—acquisitions, partnerships, expanded CRISPR offerings and cross‑regional alliances—feature prominently as companies seek to shorten model generation timelines, increase throughput for compound testing, and offer bundled preclinical services that reduce sponsor time‑to‑answer and support regulatory submissions in an evolving global market.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for animal model market by geography and historical trend. The scope of the report extends to sizing of the animal model market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Charles River Laboratories, The Jackson Laboratory (JAX), Taconic Biosciences, genOway, Janvier Labs, Biocytogen, Cyagen, Crown Bioscience, Inotiv, and Envigo (now part of larger service groups) are widely recognized as ten major companies shaping the global animal model market. Charles River is a market leader with an integrated portfolio spanning standard and specialized strains, genetically engineered models, phenotyping and regulatory support, and a global production and distribution network that serves pharmaceutical, biotech, CRO and academic clients. The Jackson Laboratory is notable for its long history in transgenic and targeted mutant mouse development, deep genetics expertise, extensive strain repositories and phenotyping resources used across translational research and preclinical discovery. Taconic distinguishes itself through custom genetically engineered rodent models, immuno‑oncology and microbiome models, and integrated breeding and colony management platforms that support rapid turnaround for complex study requirements. genOway and Janvier Labs together represent European strengths: genOway for proprietary platforms delivering reproducible gene‑edited rodent and cell models tailored to regulatory needs, and Janvier for high‑quality breeding, traceability and biosecurity that underpin neuroscience, pharmacology and infectious‑disease research in the region.
Biocytogen and Cyagen are major China‑based providers that have scaled rapid, cost‑competitive CRISPR and gene‑targeting pipelines to meet rising regional and global demand for humanized, immuno‑oncology and multi‑allelic models; both emphasize fast model generation, validation and commercial production capacity for biotech and pharma customers. Crown Bioscience and Inotiv (including acquired units) operate as vertically integrated service providers and CRO partners that combine model provision with in vivo study execution, phenotyping and toxicology services—Crown with strong translational oncology and Asia‑Pacific presence, and Inotiv with broad toxicology, surgical and specialized model capabilities across North America and Europe. Envigo, historically a major supplier of research models with a focus on welfare and flexible logistics, has been folded into larger service portfolios and remains cited among core capacity holders in industry analyses. These companies collectively respond to market drivers such as growth in oncology and immunology research, wider adoption of CRISPR/Cas gene editing, and demand for humanized and disease‑specific models while contending with regulatory and ethical pressures that encourage refinement and alternatives.
Market positioning among these ten firms reflects differences in specialization, scale and service integration: Charles River and JAX emphasize breadth, IP and translational resources; Taconic, Cyagen and genOway prioritize custom engineered models and fast CRISPR pipelines; Biocytogen and Crown leverage regional scale and oncology focus; Janvier and Envigo highlight breeding quality, biosecurity and traceability; and Inotiv emphasizes end‑to‑end CRO capabilities and toxicology services. Strategic moves—acquisitions, partnerships, expanded CRISPR offerings and cross‑regional alliances—feature prominently as companies seek to shorten model generation timelines, increase throughput for compound testing, and offer bundled preclinical services that reduce sponsor time‑to‑answer and support regulatory submissions in an evolving global market.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.